Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach.
暂无分享,去创建一个
[1] S. Berson,et al. Immunoassay of Endogenous Plasma Insulin in Man , 1960 .
[2] K. Zierler,et al. Forearm metabolism in obesity and its response to intra-arterial insulin. Characterization of insulin resistance and evidence for adaptive hyperinsulinism. , 1962, The Journal of clinical investigation.
[3] E. Newsholme,et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.
[4] R. Kreisberg,et al. Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver. , 1966, Proceedings of the National Academy of Sciences of the United States of America.
[5] J. Hirsch,et al. The role of adipose cell size and adipose tissue insulin sensitivity in the carbohydrate intolerance of human obesity. , 1968, The Journal of clinical investigation.
[6] C. Park,et al. Control of gluconeogenesis in liver. IV. Differential effects of fatty acids and glucagon on ketogenesis and gluconeogenesis in the perfused rat liver. , 1969, The Journal of biological chemistry.
[7] P. Björntorp,et al. Insulin Secretion in Relation to Adipose Tissue in Men , 1971, Diabetes.
[8] E. A. Sims,et al. Endocrine and metabolic effects of experimental obesity in man. , 1973, Recent progress in hormone research.
[9] K. Kim,et al. Mechanism of palmityl coenzyme A inhibition of liver glycogen synthase. , 1977, The Journal of biological chemistry.
[10] R. DeFronzo,et al. Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[11] D. Brown,et al. Immune response in the mutant diabetic C57BL/Ks-dt+ mouse. Discrepancies between in vitro and in vivo immunological assays. , 1978, The Journal of clinical investigation.
[12] R. DeFronzo,et al. Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding. , 1978, The Journal of clinical investigation.
[13] R. Chandra. Cell-mediated immunity in genetically obese C57BL/6J ob/ob) mice. , 1980, The American journal of clinical nutrition.
[14] J. Olefsky,et al. Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects. , 1980, The Journal of clinical investigation.
[15] P. Savage,et al. Diabetes incidence in Pima indians: contributions of obesity and parental diabetes. , 1981, American journal of epidemiology.
[16] J. Hirsch,et al. Effects of altered adipose tissue morphology on plasma insulin levels in the rat. , 1981, American Journal of Physiology.
[17] E. A. Sims,et al. Familial partial lipodystrophy: complications of obesity in the non-obese? , 1982, Metabolism: clinical and experimental.
[18] R. DeFronzo,et al. Effect of long chain triglyceride infusion on glucose metabolism in man. , 1982, Metabolism: clinical and experimental.
[19] P. Tippett,et al. An allosteric model for the inhibition of glucokinase by long chain acyl coenzyme A. , 1982, The Journal of biological chemistry.
[20] R. DeFronzo,et al. Effect of fatty acids on glucose production and utilization in man. , 1983, The Journal of clinical investigation.
[21] R. DeFronzo,et al. Regulation of Splanchnic and Peripheral Glucose Uptake by Insulin and Hyperglycemia in Man , 1983, Diabetes.
[22] G. Reaven,et al. In vitro insulin resistance of human adipocytes isolated from subjects with noninsulin-dependent diabetes mellitus. , 1983, The Journal of clinical investigation.
[23] E. Jéquier,et al. Study on lipid metabolism in obesity diabetes. , 1984, Metabolism: clinical and experimental.
[24] B V Howard,et al. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. , 1984, The Journal of clinical investigation.
[25] R. DeFronzo,et al. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. , 1985, The Journal of clinical investigation.
[26] J. Olefsky,et al. Effects of Weight Loss on Mechanisms of Hyperglycemia in Obese Non-Insulin-Dependent Diabetes Mellitus , 1986, Diabetes.
[27] E. Ferrannini,et al. Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. , 1987, Metabolism: clinical and experimental.
[28] A. Golay,et al. Relationships between plasma-free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals. , 1987, Metabolism: clinical and experimental.
[29] A. Baron,et al. Role of Hyperglucagonemia in Maintenance of Increased Rates of Hepatic Glucose Output in Type II Diabetics , 1987, Diabetes.
[30] R. DeFronzo. The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM , 1988, Diabetes.
[31] P. Arner,et al. Lipolysis in human adipocytes, effects of cell size, age and of regional differences. , 1988, Hormone and metabolic research. Supplement series.
[32] R. DeFronzo,et al. The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. , 1988, Metabolism: clinical and experimental.
[33] G. Reaven. Role of Insulin Resistance in Human Disease , 1988, Diabetes.
[34] R. DeFronzo,et al. Metabolic basis of obesity and noninsulin-dependent diabetes mellitus. , 1988, Diabetes/metabolism reviews.
[35] Yii-Der I. Chen,et al. Measurement of Plasma Glucose, Free Fatty Acid, Lactate, and Insulin for 24 h in Patients With NIDDM , 1988, Diabetes.
[36] R. DeFronzo,et al. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. , 1989, Metabolism: clinical and experimental.
[37] A N Peiris,et al. Biology of regional body fat distribution: relationship to non-insulin-dependent diabetes mellitus. , 1989, Diabetes/metabolism reviews.
[38] L. Groop,et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. , 1989, The Journal of clinical investigation.
[39] P. Bennett,et al. SEQUENTIAL CHANGES IN SERUM INSULIN CONCENTRATION DURING DEVELOPMENT OF NON-INSULIN-DEPENDENT DIABETES , 1989, The Lancet.
[40] T. Sturgill,et al. Angiotensinogen gene expression in 3T3-L1 cells. , 1989, The American journal of physiology.
[41] P. Björntorp,et al. Metabolism of adipose tissue in intraabdominal depots of nonobese men and women. , 1989, Metabolism: clinical and experimental.
[42] R. Thayer,et al. Acute and Chronic Responses of Skeletal Muscle to Endurance and Sprint Exercise , 1990, Sports Medicine.
[43] V. Grill,et al. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. , 1990, Endocrinology.
[44] M. Welsh,et al. Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. , 1990, Endocrinology.
[45] R G Shulman,et al. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. , 1990, The New England journal of medicine.
[46] P. Bennett,et al. Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis. , 1990, Diabetes/metabolism reviews.
[47] J. Snick,et al. Interleukin-6: an overview. , 1990, Annual review of immunology.
[48] P. Björntorp. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. , 1990, Arteriosclerosis.
[49] L. Groop,et al. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. , 1991, The Journal of clinical endocrinology and metabolism.
[50] R. DeFronzo,et al. Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.
[51] P. Björntorp. Metabolic Implications of Body Fat Distribution , 1991, Diabetes Care.
[52] H. Büller,et al. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans , 1991 .
[53] B. Spiegelman,et al. Adipsin and an endogenous pathway of complement from adipose cells. , 1992, The Journal of biological chemistry.
[54] B. Parry,et al. Serum tumour necrosis factor alpha and insulin resistance in gastrointestinal cancer , 1992, The British journal of surgery.
[55] R. DeFronzo,et al. The Metabolic Profile of NIDDM Is Fully Established in Glucose-Tolerant Offspring of Two Mexican-American NIDDM Parents , 1992, Diabetes.
[56] J. McGarry,et al. What if Minkowski had been ageusic? An alternative angle on diabetes. , 1992, Science.
[57] J. Lancaster,et al. Total Body Fat Content and Fat Topography Are Associated Differently With In Vivo Glucose Metabolism in Nonobese and Obese Nondiabetic Women , 1992, Diabetes.
[58] D. Kelley,et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. , 1992, The New England journal of medicine.
[59] R. Shulman,et al. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. , 1992, The Journal of clinical investigation.
[60] H. Yki-Järvinen,et al. Inhibition of Lipolysis Decreases Lipid Oxidation and Gluconeogenesis From Lactate But Not Fasting Hyperglycemia or Total Hepatic Glucose Production in NIDDM , 1993, Diabetes.
[61] R. DeFronzo,et al. Glucose metabolism during the menstrual cycle. Assessment with the euglycemic, hyperinsulinemic clamp. , 1993, The Journal of reproductive medicine.
[62] B. Spiegelman,et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.
[63] M. Papa,et al. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. , 1993, The Journal of biological chemistry.
[64] M. Maffei,et al. Positional cloning of the mouse obese gene and its human homologue , 1994, Nature.
[65] Yun-ping Zhou,et al. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. , 1994, The Journal of clinical investigation.
[66] G A Colditz,et al. Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men , 1994, Diabetes Care.
[67] B. Spiegelman,et al. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.
[68] B. Spiegelman,et al. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.
[69] L. Rossetti,et al. Mechanisms of fatty acid-induced inhibition of glucose uptake. , 1994, The Journal of clinical investigation.
[70] P. Gilon,et al. Mechanisms of the Stimulation of Insulin Release by Saturated Fatty Acids: A Study of Palmitate Effects in Mouse β-cells , 1994, Diabetes.
[71] H. Lebovitz,et al. Does Intra-Abdominal Adipose Tissue in Black Men Determine Whether NIDDM Is Insulin-Resistant or Insulin-Sensitive? , 1995, Diabetes.
[72] Steven L. Cohen,et al. Weight-reducing effects of the plasma protein encoded by the obese gene. , 1995, Science.
[73] Yun-ping Zhou,et al. Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. , 1995, The Journal of clinical endocrinology and metabolism.
[74] C. Newgard,et al. Metabolic coupling factors in pancreatic beta-cell signal transduction. , 1995, Annual review of biochemistry.
[75] B. Spiegelman,et al. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene , 1995, Molecular and cellular biology.
[76] J Auwerx,et al. Induction of the Acyl-Coenzyme A Synthetase Gene by Fibrates and Fatty Acids Is Mediated by a Peroxisome Proliferator Response Element in the C Promoter (*) , 1995, The Journal of Biological Chemistry.
[77] Philipp E. Scherer,et al. A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes (*) , 1995, The Journal of Biological Chemistry.
[78] B. Spiegelman,et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.
[79] R. Unger. Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications , 1995, Diabetes.
[80] J. Simoneau,et al. Skeletal muscle utilization of free fatty acids in women with visceral obesity. , 1995, The Journal of clinical investigation.
[81] J. Després,et al. The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[82] J. Sturis,et al. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. , 1996, The New England journal of medicine.
[83] K. Kosaka,et al. Effects of Troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy , 1996, Diabetes Care.
[84] J. Sturis,et al. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. , 1996, The American journal of physiology.
[85] J. McGarry,et al. Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. , 1996, The Journal of clinical investigation.
[86] B. Spiegelman,et al. IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance , 1996, Science.
[87] W. Alexander,et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[88] F M Matschinsky,et al. A Lesson in Metabolic Regulation Inspired by the Glucokinase Glucose Sensor Paradigm , 1996, Diabetes.
[89] J Auwerx,et al. PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.
[90] T. Buchanan,et al. Effect of Troglitazone on Insulin Sensitivity and Pancreatic β-Cell Function in Women at High Risk for NIDDM , 1996, Diabetes.
[91] W. Martin. Effects of Acute and Chronic Exercise on Fat Metabolism , 1996, Exercise and sport sciences reviews.
[92] M. Prentki,et al. Are the β-Cell Signaling Molecules Malonyl-CoA and Cystolic Long-Chain Acyl-CoA Implicated in Multiple Tissue Defects of Obesity and NIDDM? , 1996, Diabetes.
[93] J. Olefsky,et al. Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes , 1996, Diabetes.
[94] B. Spiegelman,et al. Adipogenesis and Obesity: Rounding Out the Big Picture , 1996, Cell.
[95] J. Lehmann,et al. The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones , 1996 .
[96] F. Pi‐Sunyer,et al. Weight and non-insulin-dependent diabetes mellitus. , 1996, The American journal of clinical nutrition.
[97] R N Bergman,et al. Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. Analysis of the impact of gender, body fat, physical fitness, and life-style factors. , 1996, The Journal of clinical investigation.
[98] S. Seino. Molecular biology of the β-cell ATP-sensitive K^+ channel , 1996 .
[99] R. DeFronzo,et al. In vitro and in vivo suppression of gluconeogenesis by inhibition of pyruvate carboxylase. , 1997, Biochemical pharmacology.
[100] M. Alessi,et al. PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events , 1997, Thrombosis and Haemostasis.
[101] P. Morange,et al. Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease , 1997, Diabetes.
[102] N. Barzilai,et al. Induction of Hepatic Glucose-6-Phosphatase Gene Expression by Lipid Infusion , 1997, Diabetes.
[103] M. Byrne,et al. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. , 1997, The Journal of clinical investigation.
[104] J. Auwerx,et al. Coordinate Regulation of the Expression of the Fatty Acid Transport Protein and Acyl-CoA Synthetase Genes by PPARα and PPARγ Activators* , 1997, The Journal of Biological Chemistry.
[105] J. Samra,et al. Visceral fat in relation to health: is it a major culprit or simply an innocent bystander? , 1997, International Journal of Obesity.
[106] G. Boden. Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM , 1997, Diabetes.
[107] J. Auwerx,et al. The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.
[108] B. Goodpaster,et al. Subcutaneous Abdominal Fat and Thigh Muscle Composition Predict Insulin Sensitivity Independently of Visceral Fat , 1997, Diabetes.
[109] R. Burcelin,et al. Acute stimulation of glucose metabolism in mice by leptin treatment , 1997, Nature.
[110] R. Unger. How obesity causes diabetes in Zucker diabetic fatty rats , 1997, Trends in Endocrinology & Metabolism.
[111] N. Færgeman,et al. Role of long-chain fatty acyl-CoA esters in the regulation of metabolism and in cell signalling. , 1997, The Biochemical journal.
[112] E. Ferrannini,et al. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). , 1997, The Journal of clinical investigation.
[113] M. Jimenez-Linan,et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. , 1997, The Journal of clinical investigation.
[114] S. O’Rahilly,et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. , 1997, The Journal of clinical investigation.
[115] S. Lillioja,et al. Skeletal Muscle Triglyceride Levels Are Inversely Related to Insulin Action , 1997, Diabetes.
[116] J S Yudkin,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .
[117] J. Auwerx,et al. Pioglitazone Induces In Vivo Adipocyte Differentiation in the Obese Zucker fa/fa Rat , 1997, Diabetes.
[118] P. Arner. Regional adipocity in man. , 1997, The Journal of endocrinology.
[119] E. Eschwège,et al. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study , 1997, Diabetologia.
[120] P. Grimaldi,et al. Regulation of FAT/CD36 gene expression: further evidence in support of a role of the protein in fatty acid binding/transport. , 1997, Prostaglandins, leukotrienes, and essential fatty acids.
[121] J. Paterniti,et al. Identification, Characterization, and Tissue Distribution of Human Peroxisome Proliferator-activated Receptor (PPAR) Isoforms PPARγ2 versus PPARγ1 and Activation with Retinoid X Receptor Agonists and Antagonists* , 1997, The Journal of Biological Chemistry.
[122] R A Roth,et al. Protein kinase C modulation of insulin receptor substrate-1 tyrosine phosphorylation requires serine 612. , 1997, Biochemistry.
[123] G A Colditz,et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. , 1997, American journal of epidemiology.
[124] Z. Khuchua,et al. Elements Regulating Cardiomyocyte Expression of the Human Sarcomeric Mitochondrial Creatine Kinase Gene in Transgenic Mice* , 1997, The Journal of Biological Chemistry.
[125] R. DeFronzo. PATHOGENESIS OF TYPE 2 DIABETES: METABOLIC AND MOLECULAR IMPLICATIONS FOR IDENTIFYING DIABETES GENES , 1997 .
[126] A. Luster,et al. Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.
[127] Peter Arner,et al. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway , 1998, Diabetologia.
[128] B. Howard,et al. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with Type II diabetes , 1998, Diabetologia.
[129] I. Vauhkonen,et al. Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands. , 1998, The Journal of clinical investigation.
[130] H. Lithell,et al. Relation Between Plasma Tumor Necrosis Factor-α and Insulin Sensitivity in Elderly Men With Non–Insulin-Dependent Diabetes Mellitus , 1998 .
[131] G. Shulman,et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. , 1998, The New England journal of medicine.
[132] K. Umesono,et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.
[133] R. Evans,et al. Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.
[134] M. A. Crook,et al. Is Type II diabetes mellitus a disease of the innate immune system? , 1998, Diabetologia.
[135] K. Clément,et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction , 1998, Nature.
[136] S. Hunter,et al. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. , 1998, The American journal of medicine.
[137] B. Spiegelman. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.
[138] E. Horton,et al. Troglitazone in Combination With Sulfonylurea Restores Glycemic Control in Patients With Type 2 Diabetes , 1998, Diabetes Care.
[139] L. Fink,et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. , 1998, Journal of diabetes and its complications.
[140] S. O’Rahilly,et al. Depot-related gene expression in human subcutaneous and omental adipocytes. , 1998, Diabetes.
[141] M. Lane,et al. Leptin regulates proinflammatory immune responses. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[142] L. Sjöström,et al. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. , 1998, The Journal of clinical endocrinology and metabolism.
[143] J. Auwerx,et al. Transcriptional control of adipogenesis. , 1998, Current opinion in cell biology.
[144] K. Flegal,et al. Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.
[145] T. Buchanan,et al. Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes Mellitus , 1998, Annals of Internal Medicine.
[146] R. Unger,et al. Fatty acid-induced β cell apoptosis: A link between obesity and diabetes , 1998 .
[147] V. Fonseca,et al. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. , 1998, The Journal of clinical endocrinology and metabolism.
[148] J. Zierath,et al. Evidence Against a Direct Effect of Leptin on Glucose Transport in Skeletal Muscle and Adipocytes , 1998, Diabetes.
[149] J. H. Johnson,et al. Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[150] S. Mudaliar,et al. Lack of effect of leptin on glucose transport, lipoprotein lipase, and insulin action in adipose and muscle cells. , 1998, Endocrinology.
[151] M. Reitman,et al. Transgenic Mice Lacking White Fat: Models for Understanding Human Lipoatrophic Diabetes , 1999, Annals of the New York Academy of Sciences.
[152] Vu,et al. Plasma acylation stimulating protein, adipsin and lipids in non‐obese and obese populations , 1999, European journal of clinical investigation.
[153] K. Cianflone,et al. Acylation stimulating protein (ASP), an adipocyte autocrine: new directions. , 1999, Seminars in cell & developmental biology.
[154] T. Saruta,et al. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. , 1999, Metabolism: clinical and experimental.
[155] C. N. Coleman,et al. Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcription of cyclic AMP response element binding protein- and NF-kappa B-responsive genes. , 1999, Journal of immunology.
[156] K. Alberti,et al. Serum true insulin concentration and the risk of clinical non-insulin dependent diabetes during long-term follow-up. , 1999, International journal of epidemiology.
[157] G. Boden. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. , 1999, Proceedings of the Association of American Physicians.
[158] P. Pilch,et al. Reconstitution of Insulin-sensitive Glucose Transport in Fibroblasts Requires Expression of Both PPARγ and C/EBPα* , 1999, The Journal of Biological Chemistry.
[159] N. Barzilai,et al. Surgical removal of visceral fat reverses hepatic insulin resistance. , 1999, Diabetes.
[160] F. Schick,et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. , 1999, American journal of physiology. Endocrinology and metabolism.
[161] B. Spiegelman,et al. PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro , 1999 .
[162] B. Zinman,et al. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. , 1999, The Journal of clinical endocrinology and metabolism.
[163] R R Wing,et al. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. , 1999, Diabetes.
[164] R. Curi,et al. Comparing effects of leptin and insulin on glucose metabolism in skeletal muscle: evidence for an effect of leptin on glucose uptake and decarboxylation , 1999, International Journal of Obesity.
[165] E Moser,et al. Rapid impairment of skeletal muscle glucose transport/phosphorylation by free fatty acids in humans. , 1999, Diabetes.
[166] S. Wannamethee,et al. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. , 1999, Diabetes care.
[167] R. Bergman,et al. Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. , 1999, American journal of physiology. Endocrinology and metabolism.
[168] R. Hammer,et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy , 1999, Nature.
[169] G. Boden,et al. The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. , 1999, The Journal of clinical investigation.
[170] C. Schmitz‐Peiffer,et al. Ceramide Generation Is Sufficient to Account for the Inhibition of the Insulin-stimulated PKB Pathway in C2C12 Skeletal Muscle Cells Pretreated with Palmitate* , 1999, The Journal of Biological Chemistry.
[171] L. Orci,et al. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[172] R. Anderson,et al. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve‐week, randomized, placebo‐controlled study , 1999, Diabetes, obesity & metabolism.
[173] T Nakamura,et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.
[174] J. McGarry,et al. Fatty acids, lipotoxicity and insulin secretion , 1999, Diabetologia.
[175] F. Schick,et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. , 1999, Diabetes.
[176] L. DiPietro,et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study , 1999, Diabetologia.
[177] B. Spiegelman,et al. Cross-Regulation of C/EBPα and PPARγ Controls the Transcriptional Pathway of Adipogenesis and Insulin Sensitivity , 1999 .
[178] A. Cherrington,et al. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. , 1999, Diabetes.
[179] E. Fleck,et al. Troglitazone inhibits angiotensin II‐induced extracellular signal‐regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells , 1999, FEBS letters.
[180] J. Lehmann,et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. , 2000, Molecular cell.
[181] M. Lean,et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. , 1999, Diabetes care.
[182] W. Hsueh,et al. Insulin signaling in the arterial wall. , 1999, The American journal of cardiology.
[183] C. Bogardus,et al. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. , 1999, Diabetes.
[184] G. Lewis,et al. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. , 1999, Diabetes.
[185] P. Scifo,et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. , 1999, Diabetes.
[186] S. Woods,et al. Reduced β-cell function contributes to impaired glucose tolerance in dogs made obese by high-fat feeding. , 1999, American journal of physiology. Endocrinology and metabolism.
[187] N. Tajima,et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. , 1999, Diabetes care.
[188] Rena R Wing,et al. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. , 1999, American journal of physiology. Endocrinology and metabolism.
[189] D L Rothman,et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. , 1999, The Journal of clinical investigation.
[190] A. Prentice,et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. , 1999, The New England journal of medicine.
[191] J. Yudkin. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? , 1999, Diabetes Care.
[192] T. Willson,et al. The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.
[193] D. Turnbull,et al. Decreased insulin responsiveness of glucose uptake in cultured human skeletal muscle cells from insulin-resistant nondiabetic relatives of type 2 diabetic families. , 2000, Diabetes.
[194] P. Puigserver,et al. Transcriptional regulation of adipogenesis. , 2000, Genes & development.
[195] G. Shulman,et al. Mechanism of Insulin Resistance in A-ZIP/F-1 Fatless Mice* , 2000, The Journal of Biological Chemistry.
[196] M. Engelgau,et al. Diabetes trends in the U.S.: 1990-1998. , 2000, Diabetes care.
[197] E. Ferrannini,et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. , 2000, Diabetes.
[198] R. Bergman,et al. Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. , 2000, American journal of physiology. Endocrinology and metabolism.
[199] G. Cooney,et al. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. , 2000, American journal of physiology. Endocrinology and metabolism.
[200] S. Aronoff,et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.
[201] A. Häkkinen,et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. , 2000, Diabetes.
[202] H. Hauner,et al. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[203] S. Haffner,et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.
[204] E. Danforth. Failure of adipocyte differentiation causes type II diabetes mellitus? , 2000, Nature Genetics.
[205] C. Lister,et al. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat , 2000, Diabetes, obesity & metabolism.
[206] G. Shulman,et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. , 2000, The Journal of clinical investigation.
[207] T Nakamura,et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[208] S. Kihara,et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. , 2000, Blood.
[209] J. Pickup,et al. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. , 2000, Life sciences.
[210] C. Bogardus,et al. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance , 2000, Diabetologia.
[211] L. Mandarino,et al. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. , 2000, Diabetes.
[212] J. Hoofnagle,et al. Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes , 2000, Annals of Internal Medicine.
[213] G. Cooney,et al. Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance. , 2000, Diabetes.
[214] G. Shulman,et al. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. , 2000, Diabetes.
[215] C. Mantzoros,et al. Leptin as a Therapeutic Agent—Trials and Tribulations , 2000 .
[216] B. Goodpaster,et al. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. , 2000, The American journal of clinical nutrition.
[217] V. Fonseca,et al. Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients. , 2000, Diabetes care.
[218] R. Bergman,et al. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. , 2000, Diabetes.
[219] P. Morange,et al. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. , 2000, Diabetes.
[220] J. Olefsky. Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists , 2000 .
[221] J. Kral,et al. Subcutaneous lipectomy causes a metabolic syndrome in hamsters. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.
[222] M. Lazar,et al. A Dominant-negative Peroxisome Proliferator-activated Receptor γ (PPARγ) Mutant Is a Constitutive Repressor and Inhibits PPARγ-mediated Adipogenesis* , 2000, The Journal of Biological Chemistry.
[223] C. Kahn,et al. Unraveling the mechanism of action of thiazolidinediones. , 2000, The Journal of clinical investigation.
[224] L. Groop,et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. , 2000, Diabetes.
[225] R. Bergman,et al. Free Fatty Acids and Pathogenesis of Type 2 Diabetes Mellitus , 2000, Trends in Endocrinology & Metabolism.
[226] J. Albu,et al. Fat Distribution and Health in Obesity , 2000, Annals of the New York Academy of Sciences.
[227] P. Xu,et al. Adipose tissue deficiency, glucose intolerance, and increased atherosclerosis result from mutation in the mouse fatty liver dystrophy (fld) gene. , 2000, Journal of lipid research.
[228] R. Morrison,et al. Hormonal signaling and transcriptional control of adipocyte differentiation. , 2000, The Journal of nutrition.
[229] G. Shulman,et al. Prevention of fat-induced insulin resistance by salicylate. , 2001, The Journal of clinical investigation.
[230] G. Frühbeck,et al. Do resistin and resistin-like molecules also link obesity to inflammatory diseases?. , 2001, Annals of internal medicine.
[231] T. Funahashi,et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. , 2001, Diabetes.
[232] J. Chen,et al. Protein Kinase C-ζ Phosphorylates Insulin Receptor Substrate-1 and Impairs Its Ability to Activate Phosphatidylinositol 3-Kinase in Response to Insulin* , 2001, The Journal of Biological Chemistry.
[233] C. Deng,et al. Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[234] C. Drevon,et al. Inhibition by insulin of resistin gene expression in 3T3‐L1 adipocytes , 2001, FEBS letters.
[235] G. Bray,et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. , 2001, Metabolism: clinical and experimental.
[236] M. Cybulsky,et al. NF-κB: pivotal mediator or innocent bystander in atherogenesis? , 2001 .
[237] P. Arner,et al. Regional differences in protein production by human adipose tissue. , 2001, Biochemical Society transactions.
[238] S. Mudaliar,et al. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. , 2001, Annual review of medicine.
[239] J. Manson,et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.
[240] M. Matsuda,et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. , 2001, Diabetes care.
[241] G. Frühbeck,et al. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. , 2001, American journal of physiology. Endocrinology and metabolism.
[242] M. Stumvoll,et al. Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator--activated receptor-gamma2 gene. , 2001, Diabetes.
[243] C. Bogardus,et al. Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21--q23 and is associated with a common polymorphism in LMNA in Pima Indians. , 2001, Molecular genetics and metabolism.
[244] S. O’Rahilly,et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. , 2001, Diabetes.
[245] Ping Xu,et al. Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin , 2001, Nature Genetics.
[246] M. Lazar,et al. The hormone resistin links obesity to diabetes , 2001, Nature.
[247] R. DeFronzo,et al. Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation. , 2001, Diabetes.
[248] Wei Chen,et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. , 2001, Diabetes.
[249] P. Ridker,et al. High sensitivity C-reactive protein for predicting cardiovascular disease: an inflammatory hypothesis. , 2001, European heart journal.
[250] Michael Karin,et al. Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ , 2001, Science.
[251] S. Haffner,et al. Elevated incidence of type 2 diabetes in San Antonio, Texas, compared with that of Mexico City, Mexico. , 2001, Diabetes care.
[252] S. O’Rahilly,et al. Resistin: a new link between obesity and insulin resistance? , 2001, Clinical endocrinology.
[253] H. Lebovitz,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes , 1999 .
[254] G. Shulman,et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[255] M. Matsuda,et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients , 2001, Diabetologia.
[256] L. Rossetti,et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. , 2001, The Journal of clinical investigation.
[257] P. Tappenden,et al. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. , 2001, Clinical therapeutics.
[258] Y. Terauchi,et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.
[259] P. Scherer,et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action , 2001, Nature Medicine.
[260] M. Lazar,et al. A family of tissue-specific resistin-like molecules. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[261] S. Kahn,et al. The Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes , 2001 .
[262] M. Mozzoli,et al. Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. , 2001, Diabetes.
[263] T. Funahashi,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .
[264] B. Topp,et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. , 2001, Diabetes.
[265] J. Berger,et al. The mechanisms of action of PPARs. , 2002, Annual review of medicine.
[266] N. Ruderman,et al. Lipid-Induced Insulin Resistance in Human Muscle Is Associated With Changes in Diacylglycerol, Protein Kinase C, and IκB-α , 2002 .
[267] D. S. Worrall,et al. Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation. , 2002, The Journal of clinical endocrinology and metabolism.
[268] A. Wolffe,et al. PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis , 2002 .
[269] J. Pessin,et al. An adipocentric view of signaling and intracellular trafficking , 2002, Diabetes/metabolism research and reviews.
[270] M. Cnop,et al. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. , 2002, Diabetes.
[271] G. Shulman,et al. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β‐cell dysfunction , 2002, European journal of clinical investigation.
[272] P. Ferré,et al. Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat. , 2002, American journal of physiology. Endocrinology and metabolism.
[273] B. Spiegelman,et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. , 2002, Genes & development.
[274] B. Spiegelman,et al. C/EBP induces adipogenesis through PPAR: a unified pathway , 2002 .
[275] W. Chu,et al. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. , 2002, The Journal of clinical endocrinology and metabolism.
[276] Vincent Lebon,et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. , 2002, Diabetes.
[277] Roberto Vettor,et al. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. , 2002, Diabetes.
[278] S. Kumar,et al. Resistin, central obesity, and type 2 diabetes , 2002, The Lancet.
[279] T. Asano,et al. Resistin is regulated by C/EBPs, PPARs, and signal-transducing molecules. , 2002, Biochemical and biophysical research communications.
[280] A. Häkkinen,et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. , 2002, The Journal of clinical endocrinology and metabolism.
[281] U. Boggi,et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. , 2002, Diabetes.
[282] J. McGarry. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. , 2002, Diabetes.
[283] T. Asano,et al. Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. , 2002, Diabetes.
[284] Jing He,et al. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. , 2002, Diabetes.
[285] H. Motoshima,et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. , 2002, The Journal of clinical endocrinology and metabolism.
[286] F. Lönnqvist,et al. Mapping of Early Signaling Events in Tumor Necrosis Factor-α-mediated Lipolysis in Human Fat Cells* , 2002, The Journal of Biological Chemistry.
[287] A. Barnett,et al. Increased resistin gene and protein expression in human abdominal adipose tissue. , 2002, The Journal of clinical endocrinology and metabolism.
[288] R. A. Norman,et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. , 2002, Diabetes.
[289] Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. , 2002 .
[290] S. Mudaliar,et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. , 2002, Diabetes.
[291] M. Lazar,et al. Mechanisms Regulating Adipocyte Expression of Resistin* , 2002, The Journal of Biological Chemistry.
[292] Lee-Ming Chuang,et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. , 2002, Diabetes care.
[293] M. Matsuda,et al. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. , 2002, Metabolism: clinical and experimental.
[294] M. Lazar,et al. Resistin and obesity-associated insulin resistance , 2002, Trends in Endocrinology & Metabolism.
[295] M. Matsuda,et al. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. , 2002, Diabetes care.
[296] S. O’Rahilly,et al. Regional differences in the response of human pre-adipocytes to PPARγ and RXRα agonists , 2002 .
[297] D. Muoio,et al. Peripheral metabolic actions of leptin. , 2002, Best practice & research. Clinical endocrinology & metabolism.
[298] T. Buchanan,et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. , 2002, Diabetes.
[299] M. Reitman,et al. Leptin-replacement therapy for lipodystrophy. , 2002, The New England journal of medicine.
[300] R. Plodkowski,et al. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. , 2002, Diabetes.
[301] K. Petersen,et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. , 2002, The Journal of clinical investigation.
[302] I. G. Fantus,et al. Mechanisms of the Free Fatty Acid-induced Increase in Hepatic Glucose Production Ffa and Gluconeogenesis Hepatic Insulin Signaling , 2022 .
[303] K. Bjerve,et al. Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects. , 2003, American journal of physiology. Endocrinology and metabolism.
[304] Steven R Smith,et al. A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. , 2003, Diabetes.
[305] T. Funahashi,et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. , 2003, Diabetes care.
[306] Y. Miyazaki,et al. Tumor necrosis factor α and insulin resistance in obese type 2 diabetic patients , 2003, International Journal of Obesity.
[307] R. Dobrowsky,et al. A Role for Ceramide, but Not Diacylglycerol, in the Antagonism of Insulin Signal Transduction by Saturated Fatty Acids* , 2003, The Journal of Biological Chemistry.
[308] M. Mozzoli,et al. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. , 2003, Metabolism: clinical and experimental.
[309] Y. Miyazaki,et al. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. , 2003, Diabetes.
[310] L. J. Hardies,et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. , 2003, Diabetes.
[311] L. Rossetti,et al. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. , 2003, The Journal of clinical investigation.
[312] W. Waldhäusl,et al. Insulin production rate, hepatic insulin retention and splanchnic carbohydrate metabolism after oral glucose ingestion in hyperinsulinaemic Type 2 (non-insulin-dependent) diabetes mellitus , 1982, Diabetologia.
[313] L. J. Hardies,et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. , 2004, The Journal of clinical endocrinology and metabolism.
[314] G. Paolisso,et al. Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects , 1995, Diabetologia.
[315] Thomas R. Riley,et al. A Randomized Double-blind Placebo-controlled Trial , 2004 .
[316] G. Reaven,et al. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance , 2004, Diabetologia.
[317] E. Jéquier,et al. Glucose storage and oxidation in different degrees of human obesity measured by continuous indirect calorimetry , 2004, Diabetologia.
[318] G. Reaven,et al. The fourth Musketeer — from Alexandre Dumas to Claude Bernard , 2006, Diabetologia.